Kymera Therapeutics, Inc. (KYMR)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$110.76-0.08%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Kymera Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	4.29M
EPS	—	-1.254
Annual ending 2026-12-31
Revenue	—	104.8M
EPS	—	-3.856
Annual ending 2027-12-31
Revenue	—	38.88M
EPS	—	-5.103

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash balance near $1.6 billion with runway to 2029	A primary condition in Kymera Therapeutics, Inc.'s published investment case. The stated target is >= $1.6 billion.	Intact	Cash falls below $1 billion before 2029	Cash and cash equivalents: $124.477M FY2026-Q2; GAAP. Published target: >= $1.6 billion. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source date unavailable124,477,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating losses improve toward negative $84 million next quarter	Operating losses improved from -$97.9M to -$84.15M in the last quarter.	Intact	Operating losses worsen beyond -$100 million next quarter	Operating income: $-75.607M FY2026-Q2; GAAP. Published target: <= -$84 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 5, 2026-75,607,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b7ae2f36-72db-4daf-9339-d56796a27fd2. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue grows above $34 million next quarter	A primary condition in Kymera Therapeutics, Inc.'s published investment case. The stated target is >= $34 million.	Intact	Revenue falls below $20 million next quarter	Revenue: $65M FY2026-Q2; GAAP. Published target: >= $34 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 5, 202665,000,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b7ae2f36-72db-4daf-9339-d56796a27fd2. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-5.10

$-4.29 → $-5.10 · observed estimates

FY2027 revenue$0.04B

$0.04B → $0.04B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-4.29	$43,092,224	16 / 16
2026-07-25	$-4.29	$43,092,224	16 / 16
2026-07-26	$-4.29	$43,092,224	16 / 16
2026-07-27	$-4.29	$43,092,224	16 / 16
2026-07-28	$-4.29	$43,092,224	16 / 16
2026-07-29	$-4.35	$41,021,170	20 / 21
2026-07-30	$-4.35	$41,021,170	20 / 21
2026-07-31	$-4.36	$41,094,470	21 / 22
2026-08-01	$-4.30	$43,070,396	16 / 16
2026-08-02	$-4.36	$41,094,470	21 / 22
2026-08-03	$-4.36	$41,094,470	21 / 22
2026-08-04	$-4.36	$41,094,470	21 / 22
2026-08-05	$-4.36	$41,094,470	21 / 22
2026-08-06	$-4.30	$43,070,396	17 / 17
2026-08-07	$-4.78	$41,413,653	17 / 16
2026-08-08	$-4.78	$41,413,653	17 / 16
2026-08-09	$-4.78	$41,413,653	17 / 16
2026-08-10	$-4.73	$51,046,130	21 / 18
2026-08-12	$-4.96	$45,200,730	20 / 20
2026-08-13	$-4.96	$45,200,730	20 / 20
2026-08-14	$-4.78	$41,413,653	17 / 16
2026-08-15	$-4.78	$41,413,653	17 / 16
2026-08-16	$-4.78	$41,413,653	17 / 16
2026-08-17	$-4.78	$41,413,653	17 / 16
2026-08-18	$-4.78	$41,413,653	17 / 16
2026-08-19	$-4.78	$41,413,653	17 / 16
2026-08-20	$-4.98	$41,331,119	16 / 16
2026-08-21	$-4.98	$41,331,119	16 / 16
2026-08-22	$-4.98	$41,331,119	16 / 16
2026-08-23	$-4.98	$41,331,119	16 / 16
2026-08-24	$-4.98	$41,331,119	16 / 16
2026-08-25	$-4.98	$41,331,119	16 / 16
2026-08-26	$-4.98	$41,331,119	16 / 16
2026-08-27	$-4.98	$41,331,119	16 / 16
2026-08-28	$-4.98	$41,331,119	16 / 16
2026-08-29	$-4.94	$41,331,119	17 / 16
2026-08-30	$-4.94	$41,331,119	17 / 16
2026-08-31	$-4.94	$41,331,119	17 / 16
2026-09-01	$-4.96	$40,649,301	17 / 16
2026-09-02	$-4.96	$40,649,301	17 / 16
2026-09-03	$-4.96	$40,649,301	17 / 16
2026-09-04	$-4.96	$40,649,301	17 / 16
2026-09-05	$-4.96	$40,649,301	17 / 16
2026-09-06	$-4.96	$40,649,301	16 / 15
2026-09-07	$-4.96	$40,649,301	16 / 15
2026-09-08	$-4.97	$40,204,030	16 / 15
2026-09-09	$-4.97	$40,204,030	16 / 15
2026-09-10	$-4.97	$40,204,030	16 / 15
2026-09-11	$-4.97	$40,204,030	16 / 15
2026-09-12	$-4.97	$40,204,030	16 / 15
2026-09-13	$-4.97	$40,204,030	16 / 15
2026-09-14	$-4.97	$40,204,030	16 / 15
2026-09-15	$-4.99	$40,204,030	16 / 15
2026-09-16	$-4.99	$40,204,030	16 / 15
2026-09-17	$-4.99	$40,204,030	16 / 15
2026-09-18	$-4.99	$40,204,030	16 / 15
2026-09-19	$-4.99	$40,204,030	16 / 15
2026-09-20	$-4.99	$40,204,030	16 / 15
2026-09-21	$-4.99	$40,204,030	16 / 15
2026-09-22	$-4.99	$40,204,030	16 / 15
2026-09-23	$-4.99	$40,205,458	16 / 15
2026-09-24	$-4.99	$40,205,458	16 / 15
2026-09-25	$-5.11	$38,377,938	16 / 16
2026-09-26	$-5.11	$38,377,938	16 / 16
2026-09-27	$-5.11	$38,377,938	16 / 16
2026-09-28	$-5.11	$38,377,938	16 / 16
2026-09-29	$-5.11	$38,377,938	16 / 16
2026-09-30	$-5.11	$38,377,938	16 / 16
2026-10-01	$-5.11	$38,377,938	16 / 16
2026-10-02	$-5.11	$38,377,938	16 / 16
2026-10-03	$-5.11	$38,377,938	16 / 16
2026-10-04	$-5.11	$38,377,938	16 / 16
2026-10-05	$-5.11	$38,377,938	16 / 16
2026-10-06	$-5.11	$38,377,938	16 / 16
2026-10-07	$-5.09	$38,377,938	16 / 16
2026-10-08	$-5.09	$38,377,938	16 / 16
2026-10-09	$-5.09	$38,377,938	16 / 17
2026-10-10	$-5.09	$38,377,938	16 / 17
2026-10-11	$-5.10	$38,883,245	16 / 17
2026-10-12	$-5.10	$38,883,245	17 / 17
2026-10-13	$-5.10	$38,883,245	17 / 17
2026-10-14	$-5.10	$38,883,245	17 / 17
2026-10-15	$-5.10	$38,883,245	17 / 17
2026-10-16	$-5.10	$38,883,245	17 / 17
2026-10-17	$-5.10	$38,883,245	17 / 17
2026-10-18	$-5.10	$38,883,245	17 / 17
2026-10-19	$-5.10	$38,883,245	17 / 17
2026-10-20	$-5.10	$38,883,245	17 / 17
2026-10-21	$-5.10	$38,883,245	17 / 17
2026-10-22	$-5.10	$38,883,245	17 / 17
2026-10-23	$-5.10	$38,883,245	17 / 17
2026-10-24	$-5.10	$38,883,245	17 / 17

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	23	1
2026-06-01	23	1
2026-07-01	22	3
2026-08-01	21	3
2026-09-01	21	3
2026-10-01	22	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 22 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Raymond JamesOct 8

$140.00New observation · no comparable prior

$0$77.00$154.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash balance near $1.6 billion with runway to 2029Cash and cash equivalents: $124.477M
Operating losses improve toward negative $84 million next quarterOperating income: $-75.607M
Revenue grows above $34 million next quarterRevenue: $65M

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.5%Typical daily move · historical

Downside history

-27.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Kymera Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology business, where long-term value depends on advancing drug candidates through trials. The thesis is intact, with recent signals mildly favorable, but execution quality remains fragile and overall risk is elevated.

What's priced into Kymera Therapeutics, Inc.

The valuation model indicates a premium versus peers, with a meaningful expectations gap, though confidence in that assessment is low. The evidence points to investors assigning value to the company’s future potential, but does not show that the full combination of weak execution, expensive valuation, and turbulent conditions is priced in.

What the fundamentals likely do

Near term, recent financial performance has remained in the top half of its industry, and an August earnings beat improved the signal. Management has advanced KT-621 enrollment ahead of schedule, expects data by year-end 2026, and plans Phase 3 trials by mid-2027; KT-579 data are expected in late 2026. Cash and investments were $1.5 billion in 2026-Q2, with runway stated to extend into 2029, but the business remains loss-making and trial execution carries elevated risk.

What Kymera Therapeutics, Inc. hinges on

The multi-year thesis hinges on clinical data supporting KT-621 and KT-579, while management maintains its development timelines and cash runway. A guidance cut would be a meaningful negative, while continued strength from major healthcare peers could support the sector backdrop; weakening employment data could raise recession concerns across healthcare stocks.